Skip to main content

Table 2 Gene expression and risk of recurrence, overall and by race, from CBCS Phase 3, 2008–2013

From: Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study

 

Overall (n = 938)

White (n = 465)

Black (n = 473)

Gene

Recurrence/n

HRb (95% CI)

HRc (95% CI)

Recurrence/n

HRb (95% CI)

HRc (95% CI)

Recurrence/n

HRb (95% CI)

HRc (95% CI)

ACOX2

  ≤ Median

66/469

1.00

1.00

25/206

1.00

1.00

41/263

1.00

1.00

  > Median

45/469

0.65 (0.44–0.96)

0.88 (0.58–1.32)

17/259

0.44 (0.24–0.83)

0.68 (0.35–1.32)

28/210

0.84 (0.51–1.37)

1.09 (0.65–1.82)

 Log2

 

0.94 (0.83–1.06)

1.05 (0.93–1.18)

 

0.81 (0.64–1.01)

0.99 (0.79–1.23)

 

1.01 (0.88–1.17)

1.09 (0.95–1.25)

MUC1

  ≤ Median

72/474

1.00

1.00

24/179

1.00

1.00

48/295

1.00

1.00

  > Median

39/464

0.57 (0.38–0.85)

0.89 (0.57–1.40)

18/286

0.38 (0.21–0.71)

0.62 (0.30–1.26)

21/178

0.71 (0.43–1.19)

1.04 (0.58–1.86)

 Log2

 

0.87 (0.79–0.95)

0.97 (0.87–1.08)

 

0.77 (0.67–0.88)

0.88 (0.74–1.04)

 

0.93 (0.83–1.05)

1.02 (0.89–1.18)

FAM177A1

  ≤ Median

47/468

1.00

1.00

16/211

1.00

1.00

31/257

1.00

1.00

  > Median

64/470

1.32 (0.89–1.95)

1.63 (1.09–2.46)

26/254

1.05 (0.53–2.06)

1.37 (0.69–2.73)

38/216

1.44 (0.89–2.35)

1.73 (1.04–2.87)

 Log2

 

1.14 (0.86–1.50)

1.33 (1.01–1.73)

 

1.14 (0.68–1.92)

1.46 (0.90–2.39)

 

1.14 (0.81–1.59)

1.28 (0.92–1.77)

GSTT2

  ≤ Median

51/471

1.00

1.00

22/250

1.00

1.00

29/221

1.00

1.00

  > Median

60/467

1.06 (0.72–1.55)

1.27 (0.86–1.88)

20/215

0.97 (0.53–1.78)

1.26 (0.68–2.34)

40/252

1.18 (0.72–1.93)

1.36 (0.82–2.26)

  Log2

 

1.01 (0.92–1.11)

1.07 (0.97–1.18)

 

0.96 (0.82–1.12)

1.03 (0.88–1.20)

 

1.06 (0.93–1.20)

1.11 (0.97–1.26)

PSPH

  ≤ Median

41/472

1.00

1.00

13/228

1.00

1.00

28/244

1.00

1.00

  > Median

70/466

1.71 (1.12–2.61)

1.76 (1.15–2.68)

29/237

1.79 (0.87–3.71)

2.04 (1.00–4.15)

41/229

1.66 (0.98–2.80)

1.69 (1.00–2.85)

 Log2

 

1.18 (1.00–1.41)

1.18 (1.00–1.39)

 

1.32 (0.95–1.84)

1.36 (0.98–1.87)

 

1.15 (0.94–1.40)

1.14 (0.94–1.38)

PSPHL

  ≤ Median

40/474

1.00

1.00

25/341

1.00

1.00

15/133

1.00

1.00

  > Median

71/464

1.52 (0.95–2.44)

1.33 (0.83–2.15)

17/124

1.74 (0.93–3.26)

1.53 (0.80–2.92)

54/340

1.42 (0.72–2.81)

1.24 (0.62–2.48)

 Log2

 

1.14 (1.00–1.31)

1.09 (0.95–1.26)

 

1.19 (0.96–1.48)

1.10 (0.87–1.39)

 

1.16 (0.97–1.38)

1.10 (0.92–1.32)

SQLE

  ≤ Median

41/468

1.00

1.00

17/273

1.00

1.00

24/195

1.00

1.00

  > Median

70/470

1.47 (0.99–2.17)

1.09 (0.73–1.64)

25/192

1.97 (1.06–3.65)

1.40 (0.72–2.72)

45/278

1.23 (0.75–2.03)

0.96 (0.58–1.60)

 Log2

 

1.31 (1.13–1.52)

1.20 (1.03–1.41)

 

1.40 (1.09–1.80)

1.21 (0.91–1.59)

 

1.27 (1.06–1.53)

1.19 (0.98–1.44)

TYMS

  ≤ Median

35/469

1.00

1.00

19/282

1.00

1.00

16/187

1.00

1.00

  > Median

76/469

1.93 (1.27–2.92)

1.11 (0.67–1.84)

23/183

1.70 (0.91–3.18)

0.65 (0.29–1.47)

53/286

2.09 (1.18–3.68)

1.50 (0.77–2.90)

 Log2

 

1.37 (1.15–1.64)

1.04 (0.83–1.30)

 

1.38 (1.02–1.85)

0.84 (0.61–1.15)

 

1.34 (1.06–1.69)

1.08 (0.80–1.46)

MRE Scorea

 –8 to –2

25/367

1.00

1.00

9/207

1.00

1.00

16/160

1.00

1.00

 –1 to 3

36/336

1.48 (0.88–2.48)

1.14 (0.67–1.94)

16/169

1.93 (0.83–4.47)

1.67 (0.72–3.85)

20/167

1.18 (0.61–2.30)

0.88 (0.44–1.76)

 4 to 8

50/235

3.03 (1.80–5.07)

2.10 (1.22–3.62)

17/89

4.42 (1.89–10.32)

2.88 (1.17–7.11)

33/146

2.44 (1.29–4.62)

1.78 (0.91–3.49)

 Trend

 

1.15 (1.09–1.22)

1.11 (1.04–1.19)

 

1.19 (1.08–1.31)

1.14 (1.03–1.27)

 

1.14 (1.05–1.23)

1.11 (1.02–1.20)

  1. RNA counts were normalized log2-transformed prior to analysis; analyses exclude women with unknown stage and stage IV breast cancer
  2. Log2 = continuous normalized log2-transformed gene expression
  3. CI confidence interval, HR hazard ratio
  4. aMulti-gene race-associated expression (MRE) score based on eight genes with higher scores indicating worse risk or recurrence: for ACOX2 and MUC1, ≤ median = 1 vs > median = –1; for FAM177A1, GSTT2, PSPH, PSPHL, SQLE, and TYMS, ≤ median = –1 vs > median = 1
  5. bAdjusted for age, race (black vs. white), and codeset, as appropriate
  6. cAdjusted for age, race (black vs. white), codeset, PAM50 subtype (luminal A, luminal B, HER2-enriched, basal-like, or normal-like), and risk of recurrence score with tumor size (ROR-PT; low, medium, or high), as appropriate
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us